p53 Binds to Estrogen Receptor 1 Promoter in Human Breast Cancer Cells

被引:22
作者
Rasti, Mozhgan [1 ]
Arabsolghar, Rita [1 ]
Khatooni, Zahed [1 ]
Mostafavi-Pour, Zoherh [1 ]
机构
[1] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Recombinant Prot Lab, Shiraz, Iran
关键词
Breast cancer; Estrogen receptor 1; Methylated promoter; p53; Epigenetic; ESTROGEN-RECEPTOR-ALPHA; HISTONE DEACETYLASE INHIBITION; CPG-ISLAND METHYLATION; IARC TP53 DATABASE; MUTANT P53; TRANSCRIPTIONAL REPRESSION; DNA METHYLATION; ER-ALPHA; GENE; EXPRESSION;
D O I
10.1007/s12253-011-9423-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p53 is a tumor suppressor protein that regulates estrogen receptor 1 (ESR1) expression. To investigate the mechanism of ESR1 gene regulation by p53, chromatin immunoprecipitation was applied to assess the binding of p53, DNMT1, HDAC1 and MeCP2 to both silenced ESR1 promoter in MDA-MB-468 cells and active ESR1 promoter in MCF-7 breast cancer cells. The results of chromatin immunoprecipitation experiments showed that p53 protein binds to both unmethylated CpG island of the ESR1 promoter in the ER-positive MCF-7 and the hypermethylated ESR1 promoter in the ER-negative MDA-MB-468 cells. However, repression complex including DNMT1, HDAC1 and MeCP2 is only associated with silenced ESR1 in ER-negative MDA-MB-468 human breast cancer cells. In addition, ectopically expressed wild type p53 failed to reactivate the ESR1 gene in these cells. These results suggest that specific p53 mutations may contribute to loss of estrogen receptor alpha expression in breast tumors and also support the hypothesis that mutant p53 is likely to impact DNA methylation.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 42 条
[1]   KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERα [J].
Akaogi, K. ;
Nakajima, Y. ;
Ito, I. ;
Kawasaki, S. ;
Oie, S-H ;
Murayama, A. ;
Kimura, K. ;
Yanagisawa, J. .
ONCOGENE, 2009, 28 (32) :2894-2902
[2]  
Amaral JD, 2010, DISCOV MED, V9, P145
[3]   Regulation of estrogen receptor-α expression by the tumor suppressor gene p53 in MCF-7 cells [J].
Angeloni, SV ;
Martin, MB ;
Garcia-Morales, P ;
Castro-Galache, MD ;
Ferragut, JA ;
Saceda, M .
JOURNAL OF ENDOCRINOLOGY, 2004, 180 (03) :497-504
[4]  
AVILA MA, 1994, CANCER RES, V54, P2424
[5]  
Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.3.CO
[6]  
2-B
[7]   TP53 status and response to chemotherapy in breast cancer [J].
Bertheau, Philippe ;
Espie, Marc ;
Turpin, Elisabeth ;
Lehmann, Jacqueline ;
Plassa, Louis-Francois ;
Varna, Mariana ;
Janin, Anne ;
de The, Hugues .
PATHOBIOLOGY, 2008, 75 (02) :132-139
[8]   Aberrant CpG-island methylation has non-random and tumour-type-specific patterns [J].
Costello, JF ;
Frühwald, MC ;
Smiraglia, DJ ;
Rush, LJ ;
Robertson, GP ;
Gao, X ;
Wright, FA ;
Feramisco, JD ;
Peltomäki, P ;
Lang, JC ;
Schuller, DE ;
Yu, L ;
Bloomfield, CD ;
Caligiuri, MA ;
Yates, A ;
Nishikawa, R ;
Huang, HJS ;
Petrelli, NJ ;
Zhang, XL ;
O'Dorisio, MS ;
Held, WA ;
Cavenee, WK ;
Plass, C .
NATURE GENETICS, 2000, 24 (02) :132-138
[9]   Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2 [J].
Dhar, Gopal ;
Banerjee, Snigdha ;
Dhar, Kakah ;
Tawfik, Ossama ;
Mayo, Matthew S. ;
VanVeldhuizen, Peter J. ;
Banerjee, Sushanta K. .
CANCER RESEARCH, 2008, 68 (12) :4580-4587
[10]   CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future [J].
Esteller, M .
ONCOGENE, 2002, 21 (35) :5427-5440